The US Food and Drug Administration (FDA) has cleared NeurAxis’ percutaneous electrical nerve field stimulation (PENFS) system for treating pain linked with a chronic type of gastrointestinal disorder.

NeurAxis’ device is indicated for the treatment of functional abdominal pain (FAP) associated with functional dyspepsia (FD) in patients aged eight years and above.

Placed behind a patient’s ear, Indiana-based NeurAxis’ IB-Stim delivers electrical impulses into cranial nerve bundles located in the ear, targeting specific brain regions that help reduce FD-associated pain.